Actively Recruiting
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Led by AstraZeneca · Updated on 2026-04-17
50
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
CONDITIONS
Official Title
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 618 years
- Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
- Newly prescribed acalabrutinib monotherapy within the previous 4 weeks before study enrollment
- Monotherapy means no other anti-leukemic drugs within 30 days before or after starting acalabrutinib
- Treatment-na�efve or relapsed/refractory CLL
- Ability and willingness to provide informed consent
You will not qualify if you...
- Not meeting all inclusion criteria
- Prior treatment with any BTK inhibitor
- Currently participating in other clinical trials
- Pregnant or breastfeeding females
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Minsk, Belarus
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here